Citigroup Inc Silence Therapeutics PLC Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
A detailed history of Citigroup Inc transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Citigroup Inc holds 1,773 shares of SLN stock, worth $11,028. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,773
Previous 3,474
48.96%
Holding current value
$11,028
Previous $20,000
55.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SLN
# of Institutions
56Shares Held
20.6MCall Options Held
22.8KPut Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$18.9 Million3.59% of portfolio
-
Siren, L.L.C. New York, NY2.91MShares$18.1 Million0.87% of portfolio
-
Redmile Group, LLC San Francisco, CA2.16MShares$13.5 Million1.53% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.85MShares$11.5 Million0.9% of portfolio
-
Morgan Stanley New York, NY1.21MShares$7.54 Million0.0% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $223M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...